Samotolisib

• Description :

  Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations[1][2].

• Product Name Alternative :

  LY3023414

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  Autophagy; DNA-PK; mTOR; PI3K

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/LY3023414.html

• Purity :

  99.27

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(N1C[C@@H](OC)C)N(C)C2=C1C3=CC(C4=CC(C(C)(O)C)=CN=C4)=CC=C3N=C2

• Molecular Formula :

  C23H26N4O3

• Molecular Weight :

  406.48

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Wei L, et al. Genomic profiling is predictive of response to CDDP treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. 2016 Nov 22;7 (47) :76374-76389.|[2]Smith MC, et al. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Mol Cancer Ther. 2016 Oct;15 (10) :2344-2356

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  MTOR; mTORC1; mTORC2; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

• CAS Number :

  [1386874-06-1]